37 CFR §1.823
Verified against eCFR.gov as of June 20, 2026View official text on eCFR.gov ↗
- (a)The “Sequence Listing” must comply with the following:
- (1)The order and presentation of the items of information in the “Sequence Listing” shall conform to the arrangement in appendix G to this subpart. The submission of those items of information designated with an “M” is mandatory. The submission of those items of information designated with an “O” is optional.
- (2)Each item of information shall begin on a new line, with the numeric identifier enclosed in angle brackets, as shown in appendix G to this subpart.
- (3)Set forth numeric identifiers <110> through <170> at the beginning of the “Sequence Listing.”
- (4)Include each disclosed nucleotide and/or amino acid sequence, as defined in § 1.821(a).
- (5)Assign a separate sequence identifier to each sequence, beginning with 1 and increasing sequentially by integers, and include the sequence identifier in numeric identifier <210>.
- (6)Use the code “000” in place of the sequence where no sequence is present for a sequence identifier.
- (7)Include the total number of SEQ ID NOs in numeric identifier <160>, as defined in appendix G to this subpart, whether followed by a sequence or by the code “000.”
- (8)Must not contain more than 74 characters per line.
- (b)
- (1)Unless paragraph (b)(2) of this section applies, if the “Sequence Listing” required by § 1.821(c) is submitted as an ASCII plain text file via the USPTO patent electronic filing system or on a read-only optical disc, in compliance with § 1.52(e), then the specification must contain a statement in a separate paragraph (see § 1.77(b)(5)) that incorporates by reference the material in the ASCII plain text file identifying:
- (2)If the “Sequence Listing” required by § 1.821(c) is submitted as an ASCII plain text file via the USPTO patent electronic filing system or on a read-only optical disc, in compliance with § 1.52(e) for an international application during the international stage, then incorporation by reference of the material in the ASCII plain text file is not required.
- (3)A “Sequence Listing” required by § 1.821(c) that is submitted as a PDF file (§ 1.821(c)(2)) via the USPTO patent electronic filing system or on physical sheets of paper (§ 1.821(c)(3)), setting forth the nucleotide and/or amino acid sequence and associated information in accordance with paragraph (a) of this section:
- (i)Must begin on a new page;
- (ii)Must be titled “Sequence Listing”;
- (iii)Must not include material other than the “Sequence Listing” itself;
- (iv)Must have sheets containing no more than 66 lines, with each line containing no more than 74 characters;
- (v)Should have sheets numbered independently of the numbering of the remainder of the application; and
- (vi)Should use a fixed-width font exclusively throughout.